Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Dana-Farber Cancer Institute
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06439693CT.gov The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT05483439CT.gov A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer | — | Unknown | — | — | — |
NCT05165225CT.gov Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial | — | Active Not Recruiting | — | — | — |
NCT03609047CT.gov Adjuvant Palbociclib in Elderly Patients With Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03199885CT.gov Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT03218826CT.gov PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT02568839CT.gov Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02003209CT.gov Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT01492101CT.gov The BEACON Study (Breast Cancer Outcomes With NKTR-102) | — | Completed | — | — | — |
NCT00558545CT.gov A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer | — | Terminated | — | — | — |
Show 3 more trialsShow fewer
NCT00479856CT.gov Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer | — | Terminated | — | — | — |
NCT00063934CT.gov Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer | — | Terminated | — | — | — |
NCT00004888CT.gov Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Docetaxel (this asset) | Dana-Farber Cancer Institute | P3 | BB · 71 |
| Trastuzumab | SWOG Cancer Research Network | P4 | BBB |
| Tamoxifen | Dartmouth-Hitchcock Medical Center | P4 | BBB |
| Trastuzumab Deruxtecan | SWOG Cancer Research Network | P4 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P3 | BBB |
| Zoledronate | Washington University School of Medicine | P4 | BBB |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P3 | BBB |
| Letrozole | OHSU Knight Cancer Institute | P4 | BBB |
| Dexasone | Tianjin Medical University Cancer Institute and Hospital | P4 | BBB |
+42 more in the Breast Carcinoma cohort
Other indications for Docetaxel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P4 | BBB · 73 |
| Pancreatic Adenocarcinoma | — | P2 | BBB · 72 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Docetaxel in Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/docetaxel-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →